“agios-pharmaceuticals” Archives

in
Entry Author Date Location
The Winners of the 2019 Xconomy Awards Boston Are… 09/12/19 Boston
The Finalists for the 2019 Xconomy Awards Are … 07/10/19 Boston
The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski 03/11/19 National
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More 02/15/19 National
GV Taps Ex-Agios CEO Schenkein to Lead Life Science Investments 02/11/19 San Francisco
ASH 2018: Three Up, Two Down as Big Blood Disease Meeting Rolls On 12/03/18 National
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More 11/26/18 National
New VARI Initiative Aims to Understand How Metabolism Drives Disease 10/08/18 Detroit Ann Arbor
Catch CRISPR 2.0, RNA-Targeting Drugs & More At “Disruptors” on Oct. 17 09/26/18 Boston
Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away 09/07/18 National
After a High-Speed Decade, Agios CEO David Schenkein to Step Aside 09/04/18 Boston
Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups   07/27/18 National
Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On 06/29/18 National
Rheos Medicines Launches, Backed by $60M for Immunometabolism R&D 03/22/18 Boston
CMS Starts to Cover Broad Cancer DNA Tests, Boosting Foundation, Thermo 03/19/18 Boston
Will Foundation’s FDA, CMS Nod Help Cancer DNA Tests Break Through? 12/01/17 Boston
Bio Roundup: CRISPR Advances, Obamacare Lives, FDA Nods & More 08/04/17 National
With FDA Nod, Agios, Celgene Get Speedy OK For Blood Cancer Drug 08/01/17 Boston
Stifling Immigration Is “Retrograde”: Highlights From “What’s Hot” 05/17/17 Boston
Check Out What’s Hot in Boston Biotech on May 11: Saver Rate Ends Today 04/06/17 Boston
To Infinity and Beyond: Julian Adams on Missteps and His New Job 04/03/17 Boston
Harvard’s Verdine Aims to Retire, Become Full-Time FogPharma CEO 02/23/17 Boston
Just Four Months After Series A, Delinia Sells to Celgene For $300M 01/26/17 Boston
Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More 12/16/16 National
After FDA Hold, Agios Quickly Scraps One Anemia Drug, Turns to Another 12/15/16 Boston
ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More 12/06/16 National
Third Rock Gets $616M to Grow New Crop of Biotech Startups 10/31/16 Boston
Ex-Celgene Dealmaker Tom Daniel Charts a New Course Advising Biotechs 10/17/16 New York
Biotech Roundup: CRISPR’s 3rd IPO, Gender Diversity, Buyouts & More 09/16/16 National
Celgene Plots Speedy FDA Filing for Agios Blood Cancer Drug 09/07/16 Boston
Page 1 of 5 next page »